A case-control study within a large screening trial was performed to evaluate the relationship of serum inflammation markers and lung cancer.  Of 68 evaluable markers, 11 were found to have a significant association with lung cancer.  Increasing marker levels were associated with increasing cancer risk. The findings were unrelated to cell type and smoking status.